Featured Research

from universities, journals, and other organizations

Potential New Target For Treatment Of Hormone Refractory Prostate Cancer

Date:
April 14, 2009
Source:
Cell Press
Summary:
A new study identifies a protein that modifies the androgen receptor and influences its ability to regulate target genes linked with the progression of prostate cancer. The research may also drive creation of new strategies for the treatment of advanced prostate cancer that no longer responds to traditional anti-hormone therapies.

A new study identifies a protein that modifies the androgen receptor (AR) and influences its ability to regulate target genes linked with the progression of prostate cancer. The research, published by Cell Press in the April 7th issue of the journal Cancer Cell, may also drive creation of new strategies for the treatment of advanced prostate cancer that no longer responds to traditional anti-hormone therapies.

The AR is an important mediator for the development and progression of prostate cancer, including the progression to the aggressive and often lethal androgen-independent form of the disease. "Androgen ablation therapy is the most common treatment for advanced prostate cancer," offers senior study author, Dr. Yun Qiu from the University of Maryland School of Medicine. "However, many patients inevitably develop deadly recurrent cancers, which no longer respond to androgen blockade and are resistant to current therapy."

To better understand mechanisms associated with advanced prostate cancer, Dr. Qiu and colleagues performed a screen designed to search for proteins that interact with the AR in hormone-refractory prostate cancer cells. The researchers identified RNF6 as an AR associated protein and demonstrated that RNF6 induced ubiquitination of the AR and promoted AR transcriptional activity. Ubiquitination is a common protein modification that mediates a diverse range of cellular activities. One of the best known functions of ubiquitination is to promote protein degradation. However, ubiquitination of AR by RNF6 appeared to have a stabilizing effect on AR protein.

Importantly, inhibition of RNF6 or interference with ubiquitination of AR altered expression of a specific group of AR target genes and abrogated recruitment of AR and its required coactivators to androgen-responsive regulatory regions in these genes. The researchers went on to show that expression of RNF6 was increased in human prostate cancer tissues that do not respond to androgen ablation and is required for prostate tumor growth under androgen depleted conditions.

Taken together, the findings implicate RNF6 as an important regulator of AR transcriptional activity. "Our work suggests that ubiquitination of AR, and possibly other transcription factors, may function as the scaffold for cofactor recruitment to modulate transcriptional activity and specificity," concludes Dr. Qiu. "Targeting components of the ubiquitination machinery, such as RNF6, may potentially be effective in treatment of advanced prostate cancer."

The researchers include Kexin Xu, University of Maryland School of Medicine, Baltimore, MD; Hermela Shimelis, University of Maryland School of Medicine, Baltimore, MD; Douglas E. Linn, University of Maryland School of Medicine, Baltimore, MD; Richeng Jiang, University of Maryland School of Medicine, Baltimore, MD; Xi Yang, University of Maryland School of Medicine, Baltimore, MD; Feng Sun, University of Maryland School of Medicine, Baltimore, MD; Zhiyong Guo, University of Maryland School of Medicine, Baltimore, MD; Hege Chen, University of Maryland School of Medicine, Baltimore, MD; Wei Li, University of Maryland School of Medicine, Baltimore, MD; Hegang Chen, University of Maryland School of Medicine, Baltimore, MD; Xiangtian Kong, New York University School of Medicine, New York, NY; Jonathan Melamed, New York University School of Medicine, New York, NY; Shengyun Fang, University of Maryland Biotechnology Institute, Baltimore, MD; Zhen Xiao, National Cancer Institute at Frederick, Frederick, MD; Timothy D. Veenstra, National Cancer Institute at Frederick, Frederick, MD; and Yun Qiu, University of Maryland School of Medicine, Baltimore, MD.


Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.


Journal Reference:

  1. Xu et al. Regulation of Androgen Receptor Transcriptional Activity and Specificity by RNF6-Induced Ubiquitination. Cancer Cell, 2009; 15 (4): 270-282 DOI: 10.1016/j.ccr.2009.02.021

Cite This Page:

Cell Press. "Potential New Target For Treatment Of Hormone Refractory Prostate Cancer." ScienceDaily. ScienceDaily, 14 April 2009. <www.sciencedaily.com/releases/2009/04/090406132052.htm>.
Cell Press. (2009, April 14). Potential New Target For Treatment Of Hormone Refractory Prostate Cancer. ScienceDaily. Retrieved July 26, 2014 from www.sciencedaily.com/releases/2009/04/090406132052.htm
Cell Press. "Potential New Target For Treatment Of Hormone Refractory Prostate Cancer." ScienceDaily. www.sciencedaily.com/releases/2009/04/090406132052.htm (accessed July 26, 2014).

Share This




More Health & Medicine News

Saturday, July 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins